Patents by Inventor Arthur R. Gomtsyan

Arthur R. Gomtsyan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof
    Patent number: 7875627
    Abstract: The present invention discloses fused thienopyridyl compounds of general formula (I) wherein X1-X6, R5-R7, Z1 and L are as defined in the description. The resent invention also discloses a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain, urinary incontinence, bladder overactivity, and inflammatory thermal hyperalgesia in mammals, and pharmaceutical compositions including those compounds.
    Type: Grant
    Filed: December 2, 2005
    Date of Patent: January 25, 2011
    Assignee: Abbott Laboratories
    Inventors: Sean C. Turner, Tammie K. Jinkerson, Arthur R. Gomtsyan, Chih-Hung Lee
  • Repeated Dosing of TRPV1 Antagonists
    Publication number: 20100210682
    Abstract: Disclosed herein are methods for increasing analgesic potency of TRPV1 antagonists, said methods comprise of repeated administration of the TRPV1 antagonists in a subject. Methods for treating or preventing pain by repeated administration of a TRPV1 antagonist are also discussed.
    Type: Application
    Filed: February 19, 2010
    Publication date: August 19, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Connie R. Faltynek, Arthur R. Gomtsyan, Marie P. Honore, Michael F. Jarvis, Shailen K. Joshi, Michael E. Kort, Philip R. Kym, Torben R. Neelands, Regina M. Reilly, Carol S. Surowy
  • TRPV1 ANTAGONISTS
    Publication number: 20100137360
    Abstract: Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Application
    Filed: October 15, 2009
    Publication date: June 3, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Arthur R. Gomtsyan, Eric A. Voight, Erol K. Bayburt, Jun Chen, Jerome F. Daanen, Stanley DiDomenico, Michael E. Kort, Philip R. Kym, Heath A. McDonald, Richard J. Perner, Robert G. Schmidt
  • TRPV1 ANTAGONISTS
    Publication number: 20100120846
    Abstract: Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Application
    Filed: October 15, 2009
    Publication date: May 13, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, Jun Chen, Stanley DiDomenico, Jerome F. Daanen, Michael E. Kort, Philip R. Kym, Heath A. McDonald, Richard J. Perner, Robert G. Schmidt, Eric A. Voight
  • Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof
    Patent number: 7622493
    Abstract: The present invention is directed to compounds of formula (I) wherein variables X1, X2, Y, R1a, R1b, R2a, R2b, A1, A2, A3, and A4 are as defined in the description, and methods of use to treat pain, neuropathic pain, allodynia, pain associated with inflammation or an inflammatory disease, inflammatory hyperalgesia, bladder overactivity, and urinary incontinence.
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: November 24, 2009
    Assignee: Abbott Laboratories
    Inventors: Brian S. Brown, John R. Koenig, Arthur R. Gomtsyan, Chih-Hung Lee
  • ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF
    Publication number: 20090233953
    Abstract: The present invention is directed to compounds of formula (I) wherein variables X1, X2, Y, R1a, R1b, R2a, R2, A1, A2, A3, and A4 are as defined in the description, and methods of use to treat pain, neuropathic pain, allodynia, pain associated with inflammation or an inflammatory disease, inflammatory hyperalgesia, bladder overactivity, and urinary incontinence.
    Type: Application
    Filed: May 28, 2009
    Publication date: September 17, 2009
    Applicant: ABBOTT LABORATORIES
    Inventors: Brian S. Brown, John R. Koenig, Arthur R. Gomtsyan, Chih-Hung Lee
  • TRPV1 ANTAGONISTS
    Publication number: 20090124671
    Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4, R5, m, and n are defined in the specification are TRPV1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Application
    Filed: October 23, 2008
    Publication date: May 14, 2009
    Applicant: ABBOTT LABORATORIES
    Inventors: Arthur R. Gomtsyan, Robert G. Schmidt, Erol K. Bayburt, Jerome F. Daanen, Michael E. Kort
  • AMIDE DERIVATIVES AS TRPV1 ANTAGONISTS
    Publication number: 20090062345
    Abstract: The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, and R3, are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Application
    Filed: August 8, 2008
    Publication date: March 5, 2009
    Applicant: ABBOTT LABORATORIES
    Inventors: Anil Vasudevan, Brian S. Brown, Jerome F. Daanen, Arthur R. Gomtsyan, Tammie K. Jinkerson, Ryan G. Keddy, Michael E. Kort, Philip R. Kym, Mark A. Matulenko
  • FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR
    Publication number: 20080287676
    Abstract: The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
    Type: Application
    Filed: April 30, 2008
    Publication date: November 20, 2008
    Applicant: Abbott Laboratories
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, Chih-Hung Lee, John R. Koenig, Robert G. Schmidt, Kirill A. Lukin, Gilles Chambournier, Margaret Chi-Ping Hsu, Robert M. Leanna, Russell D. Cink
  • FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR
    Publication number: 20080214524
    Abstract: Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.
    Type: Application
    Filed: February 19, 2008
    Publication date: September 4, 2008
    Applicant: ABBOTT LABORATORIES
    Inventors: CHIH-HUNG LEE, EROL K. BAYBURT, STANLEY DIDOMENICO, IRENE DRIZIN, ARTHUR R. GOMTSYAN, JOHN R. KOENIG, RICHARD J. PERNER, ROBERT G. SCHMIDT, SEAN C. TURNER, TAMMIE K. WHITE, GUO ZHU ZHENG
  • NOVEL AMIDES USEFUL FOR TREATING PAIN
    Publication number: 20080153809
    Abstract: The present invention relates to compounds of formula (I-VII) or a pharmaceutically acceptable salt or prodrug thereof, in which A, L, R6, R7 and R8 are defined herein. The present invention also relates to methods of treating pain using these compounds and pharmaceutical compositions including these compounds.
    Type: Application
    Filed: February 19, 2008
    Publication date: June 26, 2008
    Applicant: ABBOTT LABORATORIES
    Inventors: CHIH-HUNG LEE, Erol K. Bayburt, Stanley DiDomenico, Irene Drizin, Arthur R. Gomtsyan, John R. Koenig, Richard J. Perner, Robert G. Schmidt, Sean C. Turner, Tammie K. White, Guo Zhu Zheng
  • ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF
    Publication number: 20080153871
    Abstract: The present application is directed to compounds that are TRPV1 antagonists and have formula (I) wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.
    Type: Application
    Filed: December 12, 2007
    Publication date: June 26, 2008
    Applicant: Abbott Laboratories
    Inventors: Erol K. Bayburt, Jerome F. Daanen, Arthur R. Gomtsyan, Steven P. Latshaw, Chih-hung Lee, Robert G. Schmidt
  • Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Patent number: 7375126
    Abstract: The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: May 20, 2008
    Assignee: Abbott Laboratories
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, Chih-Hung Lee, John R. Koenig, Robert G. Schmidt, Kirill A. Lukin, Margaret Chi-Ping Hsu, Marvin R. Leanna, Russell D. Cink, Gilles Chambournier
  • Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor
    Patent number: 7335678
    Abstract: Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X1, X2, X3, X4, X5, R5, R6, R7, R8a, R8b, R9, Z1, Z2, and L are defined in the description.
    Type: Grant
    Filed: May 10, 2004
    Date of Patent: February 26, 2008
    Assignee: Abbott Laboratories
    Inventors: Chih-Hung Lee, Erol K. Bayburt, Stanley DiDomenico, Jr., Irene Drizin, Arthur R. Gomtsyan, John R. Koenig, Richard J. Perner, Robert G. Schmidt, Jr., Sean C. Turner, Tammie K. White, Guo Zhu Zheng
  • Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Patent number: 7074805
    Abstract: The isoquinoline compounds of formula (I) are VR1 antagonists that are useful in treating pain, inflammation, thermal hyperalgesia, urinary incontinence and bladder over activity. The “R”, “Z” and “L” variables are defined in the disclosure and the “X” variables are defined as follows: X1 is CR1; X2 is selected from the group consisting of N and CR2; X3 is selected from the group consisting of N and CR3; X4 is CR4; and X5 is selected from the group consisting of N and C.
    Type: Grant
    Filed: February 11, 2003
    Date of Patent: July 11, 2006
    Assignee: Abbott Laboratories
    Inventors: Chih-Hung Lee, Erol K. Bayburt, Stanley DiDomenico, Jr., Irene Drizin, Arthur R. Gomtsyan, John R. Koenig, Richard J. Perner, Robert G. Schmidt, Jr., Sean C. Turner, Tammie K. White, Guo Zhu Zheng
  • Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Patent number: 6933311
    Abstract: Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X1, X2, X3, X4, X5, R5, R6, R7, R8a, R8b, R9, Z1, Z2 and L are as defined in the description.
    Type: Grant
    Filed: August 5, 2003
    Date of Patent: August 23, 2005
    Assignee: Abbott Laboratories
    Inventors: Chih-Hung Lee, Erol K. Bayburt, Stanley DiDomenico, Jr., Irene Drizin, Arthur R. Gomtsyan, John R. Koenig, Richard J. Perner, Robert G. Schmidt, Jr., Sean C. Turner, Tammie K. White, Guo Zhu Zheng
  • Trisubstituted-N-[(1S)-1,2,3,4-Tetrahydro-1-naphthalenyl]benzamides which inhibit P2X3 and P2X2/3 containing receptors
    Patent number: 6831193
    Abstract: Compounds of formula (I) are novel P2X3 and P2X2/P2X3 antagonists which are useful in treating pain, urinary incontinence and bladder overactivity.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: December 14, 2004
    Assignee: Abbott Laboratories
    Inventors: Chih-Hung Lee, Richard J. Perner, Daniel P. Larson, John R. Koenig, Arthur R. Gomtsyan, Guo Zhu Zheng, Stanley DiDomenico, Andrew O. Stewart, Erol K. Bayburt
  • Fused azabicycic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor
    Publication number: 20040209884
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: May 10, 2004
    Publication date: October 21, 2004
    Inventors: Chih-Hung Lee, Erol K. Bayburt, Stanley DiDomenico, Irene Drizin, Arthur R. Gomtsyan, John R. Koenig, Richard J. Perner, Robert G. Schmidt, Sean C. Turner, Tammie K. White, Guo Zhu Zheng
  • Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Publication number: 20040157849
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: August 5, 2003
    Publication date: August 12, 2004
    Inventors: Chih-Hung Lee, Erol K. Bayburt, Stanley DiDomenico, Irene Drizin, Arthur R. Gomtsyan, John R. Koenig, Richard J. Perner, Robert G. Schmidt, Sean C. Turner, Tammie K. White, Guo Zhu Zheng
  • Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Publication number: 20030158198
    Abstract: Compound of formula (I) 1
    Type: Application
    Filed: February 11, 2003
    Publication date: August 21, 2003
    Inventors: Chih-Hung Lee, Erol K. Bayburt, Stanley DiDomenico, Irene Drizin, Arthur R. Gomtsyan, John R. Koenig, Richard J. Perner, Robert G. Schmidt, Sean C. Turner, Tammie K. White, Guo Zhu Zheng